Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PORCINE SECRETIN.
AMINOHIPPURATE SODIUM vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent